Meta-analysis of the role of Argatroban in renal replacement therapy.
- Author:
Fang-fang CAO
1
;
Hai-tao ZHANG
1
;
Xue FENG
1
;
Ruo-nan JIAO
1
Author Information
- Publication Type:Journal Article
- MeSH: Antithrombins; therapeutic use; Hemorrhage; epidemiology; Humans; Incidence; Pipecolic Acids; therapeutic use; Renal Dialysis; Renal Insufficiency; Renal Replacement Therapy; methods; Thrombosis; drug therapy
- From: Acta Academiae Medicinae Sinicae 2013;35(6):667-671
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the role of direct thrombin inhibitor argatroban in the renal replacement therapy.
METHODSElectronic databases including Cochrane library, PubMed, EMBASE, Highwire, MEDLINE, CBM, CNKI, and CSJD were searched using keywords including "Argatroban", "hemodialysis", "renal function", "renal failure", and "renal replacement therapy". A meta-analysis of all randomized controlled trials(RCTs)comparing argatroban with controls in renal replacement therapy was performed. Both the study selection and the meta-analysis were conducted according to the Cochrane Handbook for systematic reviews. Data were extracted from these trials and analyzed by RevMan 5.0 software.
RESULTSCompared with the control group, argatroban in renal replacement therapy showed no significant difference in mortality(RR=0.97, 95%CI: 0.48-1.97, P=0.93)and bleeding rate(RR=0.71, 95%CI: 0.37-1.34, P=0.29). Argatroban significantly decreased the incidence of new thrombosis in renal replacement therapy for patients with heparin-induced Thrombocytopenia(RR=0.40, 95%CI: 0.21-0.75, P=0.004). Also, argatroban significantly decreased the clotting events in extracorporeal circuit during the renal replacement therapy(RR=0.06, 95%CI: 0.01-0.23, P<0.0001). CONCLUSION Argatroban applied in renal replacement therapy can decrease the incidences of new thrombosis and clotting events in extracorporeal circuit and meanwhile will not increase the mortality and bleeding.
